Targeting Venetoclax Resistance in TP53-Mutated Acute Myeloid Leukemia

被引：0

作者：

Vanttinen, Ida ^{[1
,2
]}

Ruokoranta, Tanja ^{[1
]}

Saad, Joseph J. ^{[1
,2
]}

Kytola, Sari ^{[3
]}

Hellesoy, Monica ^{[4
]}

Gullaksen, Stein-Erik ^{[4
]}

Ettala, Pia-Sofia ^{[5
]}

Pyorala, Marja ^{[6
]}

Rimpilainen, Johanna ^{[7
]}

Siitonen, Timo ^{[8
]}

Wennerberg, Krister ^{[9
]}

Gjertsen, Bjorn T. ^{[4
,10
]}

Heckman, Caroline A. ^{[1
,2
]}

Kontro, Mika ^{[1
,2
,3
,11
]}

Kuusanmaki, Heikki ^{[1
,2
,9
,11
]}

机构：

[1] Univ Helsinki, Inst Mol Med Finland FIMM, HiLIFE, Helsinki, Finland

[2] ICAN Digital Precis Canc Med Flagship, Helsinki, Finland

[3] Helsinki Univ Hosp, Dept Hematol, Comprehens Canc Ctr, Helsinki, Finland

[4] Helse Bergen, Hematol Sect, Dept Med, Bergen, Norway

[5] Turku Univ Hosp, Dept Clin Hematol, Turku, Finland

[6] Kuopio Univ Hosp, Dept Med, Kuopio, Finland

[7] Tampere Univ Hosp, Dept Internal Med, Tampere, Finland

[8] Oulu Univ Hosp, Canc Ctr, Hematol, Oulu, Finland

[9] Univ Copenhagen, Biotech Res & Innovat Ctr BRIC, Copenhagen, Denmark

[10] Univ Bergen, Dept Clin Sci, Ctr Canc Biomarkers CCBIO, Bergen, Norway

[11] Fdn Finnish Canc Inst, Helsinki, Finland

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-189340

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia
Kong, Jinyu
Chen, Nan
Li, Mengyun
Zhang, Jian
Wu, Xiaoxia
Zong, Lihong
Wu, Depei
Song, Baoquan
Qiu, Huiying
ANNALS OF HEMATOLOGY, 2022, 101 (03) : 697 - 699
[22] Immunohistochemistry for p53 Might Lead to Prompter Treatment in TP53-Mutated Acute Myeloid Leukemia
Boiocchi, Leonardo
Crabbe, Andrew
Brunner, Andrew
Fathi, Amir T.
Hasserjian, Robert
Nardi, Valentina
MODERN PATHOLOGY, 2019, 32
[23] Immunohistochemistry for p53 Might Lead to Prompter Treatment in TP53-Mutated Acute Myeloid Leukemia
Boiocchi, Leonardo
Crabbe, Andrew
Brunner, Andrew
Fathi, Amir T.
Hasserjian, Robert
Nardi, Valentina
LABORATORY INVESTIGATION, 2019, 99
[24] Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia
Jinyu Kong
Nan Chen
Mengyun Li
Jian Zhang
Xiaoxia Wu
Lihong Zong
Depei Wu
Baoquan Song
Huiying Qiu
Annals of Hematology, 2022, 101 : 697 - 699
[25] TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations
DiGennaro, Jeremy
Sallman, David A.
ACTA HAEMATOLOGICA, 2024, 147 (02) : 176 - 186
[26] Low-dose weekly decitabine and venetoclax in TP53-mutated myeloid malignancies.
Shapiro, Lauren C.
Mantzaris, Ioannis
Shastri, Aditi
Sica, Alejandro R.
Bachier-Rodriguez, Lizamarie
Kornblum, Noah
Gritsman, Kira
Feldman, Eric Jay
Verma, Amit K.
Braunschweig, Ira
Saunthararajah, Yogen
Goldfinger, Mendel
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E19005 - E19005
[27] TP53 mutated acute myeloid leukemia
Sill, H.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 257 - 257
[28] Optimal Induction and Consolidation Strategy for Patients with Complex Karyotype and TP53-Mutated Acute Myeloid Leukemia
Jamy, Omer H.
Diebold, Kendall
Bachiashvili, Kimo
Rangaraju, Sravanti
Vachhani, Pankit
Godby, Kelly N.
Salzman, Donna
Bhatia, Ravi
BLOOD, 2022, 140 : 8959 - 8960
[29] The Current Understanding of and Treatment Paradigm for Newly-Diagnosed TP53-Mutated Acute Myeloid Leukemia
Shallis, Rory M.
Stahl, Maximilian
Bewersdorf, Jan Philipp
Zeidan, Amer M.
Testa, Ugo
Walter, Roland B.
HEMATO, 2021, 2 (04): : 748 - 763
[30] TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches
Pereira, Mariana Pinto
Herrity, Elizabeth
Kim, Dennis D. H.
ANNALS OF HEMATOLOGY, 2024, 103 (04) : 1049 - 1067

← 1 2 3 4 5 →